文献速递主动脉疾病

侧支栓塞与腹主动脉瘤腔内修复术的中期结局

Midterm outcomes of side branch embolization and endovascular abdominal aortic aneurysm repair.
PubMed 文献 · J Vasc Surg · 2023-12-08

该研究纳入2013至2021年接受初次EVAR的616例患者,比较未栓塞、仅栓塞肠系膜下动脉、栓塞肠系膜下动脉加腰动脉(含骶正中动脉)三组。结果示IMA+LA-E组持续性2型内漏和再干预发生率更低、瘤囊缩小更明显,但透视时间和剂量面积乘积更高。

要点

  • IMA+LA-E组3年持续性2型内漏发生率9.4%,低于NO-E组27.8%和IMA-E组31.7%(P=.007)。
  • 校正后NO-E组(OR 3.21)和IMA-E组(OR 4.86)持续性2型内漏风险高于IMA+LA-E组。
  • IMA+LA-E组瘤囊缩小百分比18.0%±18.8%,高于NO-E组12.1%±16.6%和IMA-E组11.4%±16.7%(P=.047)。

核心结论

  • EVAR术中预先栓塞IMA、腰动脉和骶正中动脉可降低3年随访期间持续性2型内漏和任何再干预的发生率,并促进瘤囊缩小。

研究设计与样本

  • 2013年至2021年纳入所有接受初次EVAR的患者(少数例外),共732例中616例(84.2%)纳入分析。
  • 按侧支栓塞情况分为NO-E组223例(36.2%)、IMA-E组228例(37.0%)、IMA+LA-E组165例(26.8%)。
  • IMA和LA栓塞的技术成功率分别为97.0%和74.7%。

主要发现

  • 3年时持续性2型内漏粗发生率:NO-E组27.8%、IMA-E组31.7%、IMA+LA-E组9.4%(P=.007)。
  • 多因素分析示NO-E组(OR 3.21,95%CI 1.08-9.57,P=.004)和IMA-E组(OR 4.86,95%CI 1.68-14.11,P=.004)持续性2型内漏风险高于IMA+LA-E组。
  • 3年内任何再干预:NO-E组OR 5.26(95%CI 1.76-15.70,P=.003)、IMA-E组OR 4.19(95%CI 1.38-12.67,P=.01),均高于IMA+LA-E组。
  • 瘤囊较基线缩小百分比:NO-E组12.1%±16.6%、IMA-E组11.4%±16.7%、IMA+LA-E组18.0%±18.8%(P=.047)。
  • 透视时间:NO-E组60.2±47.4分钟、IMA-E组59.3±39.5分钟、IMA+LA-E组75.5±42.8分钟(P<.0001);剂量面积乘积:NO-E组424.6±333.4 Gy cm2、IMA-E组477.7±342.4 Gy cm2、IMA+LA-E组631.8±449.1 Gy cm2(P<.0001)。

临床怎么用

  • 作者结论认为,EVAR术中预先栓塞IMA、腰动脉和骶正中动脉可降低持续性2型内漏和再干预并促进瘤囊缩小。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To analyze the effects of total side branch embolization at endovascular aneurysm repair (EVAR) for abdominal aortic aneurysms on the incidences of persistent type 2 endoleak (pT2EL), changes in sac diameter, and reintervention. METHODS: Between 2013 and 2021, all patients who underwent primary EVAR with a few exceptions were included. Side branch embolization was considered during EVAR for inferior mesenteric artery (IMA) or IMA plus lumbar artery (LA) when feasible for contrast agent use. Outcomes measured were pT2EL, sac diameters, reintervention, ruptures, and aneurysm-related mortality. Radiation exposure and safety outcomes were also reported. RESULTS: Among 732 patients who underwent EVAR, 616 (84.2%) were included. Of the 616 patients, 223 (36.2%) did not undergo side branch embolization (NO-E), whereas 228 (37.0%) underwent IMA only (IMA-E) and 165 (26.8%) underwent IMA+LA including median sacral artery (IMA+LA-E). The technical success rate of IMA and LA embolization was 97.0% and 74.7%, respectively. Crude incidences of pT2EL were significantly different from 6 months through 3 years (NO-E, 27.8%; IMA-E, 31.7%; IMA+LA-E, 9.4% at 3 years; P = .007). In the multivariate analysis adjusted for background differences, the incidences of pT2EL were significantly higher in the NO-E (odds ratio [OR], 3.21; 95% confidence intervals [CIs], 1.08-9.57; P = .004) and IMA-E (OR, 4.86; 95% CIs, 1.68-14.11; P = .004) compared with the IMA+LA-E group. Similarly, any reintervention until 3 years was significantly frequent in the NO-E (OR, 5.26; 95% CIs, 1.76-15.70; P = .003) and IMA-E group (OR, 4.19; 95% CIs, 1.38-12.67; P = .01). Surgical conversion and secondary rupture were seen only in 1 patient without any aneurysm-related mortality. Percent sac shrinkage from the baseline was significantly promoted in the IMA+LA group (NO-E, 12.1% ± 16.6%; IMA-E, 11.4% ± 16.7%; IMA+LA-E, 18.0% ± 18.8%; P = .047). Fluoroscopy time was significantly longer in the IMA+LA-E group (NO-E, 60.2 ± 47.4 minutes; IMA-E, 59.3 ± 39.5 minutes; IMA+LA-E, 75.5 ± 42.8 minutes; P < .0001), and so do the dose-area product (NO-E, 424.6 ± 333.4 Gy cm2; IMA-E, 477.7 ± 342.4 Gy cm2; IMA+LA-E, 631.8 ± 449.1 Gy cm2; P < .0001). No embolization-related complications or radiation-related adverse events were recorded. CONCLUSIONS: Pre-emptive embolization of IMA, LAs, and median sacral artery at the time of EVAR reduced the incidences of pT2EL and any reintervention and promoted sac shrinkage during the follow-up period of 3 years.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Shirasu T, Akai A, Motoki M, et al. Midterm outcomes of side branch embolization and endovascular abdominal aortic aneurysm repair. J Vasc Surg. 2023. PMID: 38070786. doi:10.1016/j.jvs.2023.12.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。